The University of Southampton
University of Southampton Institutional Repository

Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera

Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera
Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera
Background: although reduction in the JAK2V617F allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear. The purpose of this study is to determine whether a reduction in %V617F in polycythemia vera is a prerequisite to achieving hematologic remission in response to cytoreductive therapy.

Design and methods: we compared the clinical and hematologic responses to change in %V617F (molecular response) in 73 patients with polycythemia vera treated with either interferon (rIFN?-2b: 28, Peg-rIFN?-2a: 18) or non-interferon drugs (n=27), which included hydroxyurea (n=8), imatinib (n=12), dasatinib (n=5), busulfan (n=1), and radioactive phosphorus (n=1). Hematologic response evaluation employed Polycythemia Vera Study Group criteria, and molecular response evaluation, European Leukemia Net criteria.

Results: of the 46 treated with interferon, 41 (89.1%) had a hematologic response, whereas only 7 (15.2%) had a partial molecular response. Of the 27 who received non-interferon treatments, 16 (59.3%) had a hematologic response, but only 2 (7.4%) had a molecular response. Median duration of follow up was 2.8 years. Statistical agreement between hematologic response and molecular response was poor in all treatment groups.

Conclusions: generally, hematologic response was not accompanied by molecular response. Therefore, a quantitative change in %V617F is not required for clinical response in patients with polycythemia vera
0390-6078
538-542
Kuriakose, Emil
6f356b9b-df4c-4c69-91ca-9d4978077606
Vandris, Katherine
42852a40-1f83-4d34-bd50-78dd60d14335
Wang, Y. Lynn
281a4bfb-c4f7-4bb1-b883-902d17f0e04c
Chow, William
d13aa895-54ab-47bf-b3b6-e3a62d8d098c
Jones, Amy V.
3d296088-a099-45cf-b227-541ff59d800c
Christos, Paul
5c7f4df0-2352-4477-a3f0-551cef8f1c25
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Silver, Richard T.
661e0b91-4a5c-4100-9a7a-e4f1db3f3a1d
Kuriakose, Emil
6f356b9b-df4c-4c69-91ca-9d4978077606
Vandris, Katherine
42852a40-1f83-4d34-bd50-78dd60d14335
Wang, Y. Lynn
281a4bfb-c4f7-4bb1-b883-902d17f0e04c
Chow, William
d13aa895-54ab-47bf-b3b6-e3a62d8d098c
Jones, Amy V.
3d296088-a099-45cf-b227-541ff59d800c
Christos, Paul
5c7f4df0-2352-4477-a3f0-551cef8f1c25
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Silver, Richard T.
661e0b91-4a5c-4100-9a7a-e4f1db3f3a1d

Kuriakose, Emil, Vandris, Katherine, Wang, Y. Lynn, Chow, William, Jones, Amy V., Christos, Paul, Cross, Nicholas C.P. and Silver, Richard T. (2012) Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica, 97 (4), 538-542. (doi:10.3324/haematol.2011.053348). (PMID:22102708)

Record type: Article

Abstract

Background: although reduction in the JAK2V617F allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear. The purpose of this study is to determine whether a reduction in %V617F in polycythemia vera is a prerequisite to achieving hematologic remission in response to cytoreductive therapy.

Design and methods: we compared the clinical and hematologic responses to change in %V617F (molecular response) in 73 patients with polycythemia vera treated with either interferon (rIFN?-2b: 28, Peg-rIFN?-2a: 18) or non-interferon drugs (n=27), which included hydroxyurea (n=8), imatinib (n=12), dasatinib (n=5), busulfan (n=1), and radioactive phosphorus (n=1). Hematologic response evaluation employed Polycythemia Vera Study Group criteria, and molecular response evaluation, European Leukemia Net criteria.

Results: of the 46 treated with interferon, 41 (89.1%) had a hematologic response, whereas only 7 (15.2%) had a partial molecular response. Of the 27 who received non-interferon treatments, 16 (59.3%) had a hematologic response, but only 2 (7.4%) had a molecular response. Median duration of follow up was 2.8 years. Statistical agreement between hematologic response and molecular response was poor in all treatment groups.

Conclusions: generally, hematologic response was not accompanied by molecular response. Therefore, a quantitative change in %V617F is not required for clinical response in patients with polycythemia vera

This record has no associated files available for download.

More information

Published date: April 2012
Organisations: Human Development & Health

Identifiers

Local EPrints ID: 341950
URI: http://eprints.soton.ac.uk/id/eprint/341950
ISSN: 0390-6078
PURE UUID: aaa3cfc1-b5e6-4b0f-8124-7753ac245f74
ORCID for Nicholas C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 08 Aug 2012 14:29
Last modified: 15 Mar 2024 03:11

Export record

Altmetrics

Contributors

Author: Emil Kuriakose
Author: Katherine Vandris
Author: Y. Lynn Wang
Author: William Chow
Author: Amy V. Jones
Author: Paul Christos
Author: Richard T. Silver

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×